rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Tactile Systems Technology, Inc.

TCMD · Nasdaq

Health CareMedical DevicesNot moving yet

TCMD stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 11 weeks. It is 10.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 11
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$4.0M
Officials’ trades on record
5
Institutions holding
174 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

5 disclosed lines: House 1, Senate 4, executive 0; 2 people.

WhoDidAmountTraded
Tina Smith Senate: U.S. Senate eFDSenatorboughtspouse$50k–$100k12 Nov 2024filed 21 Nov 2024
Tina Smith Senate: U.S. Senate eFDSenatorboughtspouse$100k–$250k8 Nov 2023filed 20 Nov 2023
Donna E. Shalala House: U.S. House ClerkFL27bought$1k–$15k23 Jan 2019filed 27 Apr 2020
Tina Smith Senate: U.S. Senate eFDSenatorsold part ofspouse$100k–$250k1 Jun 2018filed 11 Jun 2018
Tina Smith Senate: U.S. Senate eFDSenatorsoldspouse$100k–$250k1 Jun 2018filed 11 Jun 2018

Insiders

Buy orders, 12 months0
Sale orders, 12 months9
Buyers · sellers0 · 3
WhoDidSharesTraded
Sheri Louise DoddChief Executive Officersold10,978at $29.4410 Aug 2026filed 12 Aug 2026
Elaine M. BirkemeyerCHIEF FINANCIAL OFFICERsold4,631at $24.4911 May 2026filed 13 May 2026
Sheri Louise DoddChief Executive Officersold10,993at $28.9424 Feb 2026filed 26 Feb 2026
Kristie BurnsSr. VP Mktg & Clinical Affairssold6,246at $28.9424 Feb 2026filed 26 Feb 2026
Elaine M. BirkemeyerCHIEF FINANCIAL OFFICERsold7,701at $28.9424 Feb 2026filed 26 Feb 2026
Sheri Louise DoddChief Executive Officersold14,703at $28.2823 Feb 2026filed 24 Feb 2026
Sheri Louise DoddChief Executive Officersold537at $28.6923 Feb 2026filed 24 Feb 2026
Kristie BurnsSr. VP Mktg & Clinical Affairssold4,279at $28.2823 Feb 2026filed 24 Feb 2026
Kristie BurnsSr. VP Mktg & Clinical Affairssold160at $28.6923 Feb 2026filed 24 Feb 2026
Elaine M. BirkemeyerCHIEF FINANCIAL OFFICERsold5,322at $28.2823 Feb 2026filed 24 Feb 2026
Elaine M. BirkemeyerCHIEF FINANCIAL OFFICERsold196at $28.6923 Feb 2026filed 24 Feb 2026
Kristie BurnsSr. VP Mktg & Clinical Affairssold5,139at $28.852 Jan 2026filed 6 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders174-1 on the quarter
New · exited32 · 32
Reported value$613.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,905,086$56.7M+125,640+7.1%
CADIAN CAPITAL MANAGEMENT, LPadded · filed 14 Aug 20261,576,940$47.0M+535,868+51.5%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20261,092,193$32.5M+12,477+1.2%
MORGAN STANLEYreduced · filed 13 Aug 2026979,340$29.2M-403,472−29.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026970,246$28.9M+25,149+2.7%
Driehaus Capital Management LLCadded · filed 14 Aug 2026937,783$27.9M+195,869+26.4%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026706,509$21.0M+38,175+5.7%
FEDERATED HERMES, INC.added · filed 12 Aug 2026681,153$20.3M+20,196+3.1%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPunchanged · filed 13 Aug 2026638,368$19.0M00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026586,334$17.5M+29,540+5.3%
31 Mar 2023 – 30 Jun 2026
107140172Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Sheri Louise Dodd Company insiderChief Executive Officer · last 10 Aug 20260 · 5
Elaine M. Birkemeyer Company insiderCHIEF FINANCIAL OFFICER · last 11 May 20260 · 7
Andrea Pearson Company insiderDirector · last 6 May 20260 · 0
Boyd Vindell Washington Company insiderDirector · last 6 May 20260 · 0
Carmen B. Volkart Company insiderDirector · last 6 May 20260 · 0
David Brent Shafer Company insiderDirector · last 6 May 20260 · 0
Laura G. King Company insiderDirector · last 6 May 20260 · 0
Raymond Huggenberger Company insiderDirector · last 6 May 20260 · 0
Valerie L. Asbury Company insiderDirector · last 6 May 20260 · 0
William W. Burke Company insiderDirector · last 6 May 20261 · 15
Kristie Burns Company insiderSr. VP Mktg & Clinical Affairs · last 24 Feb 20260 · 14
Daniel L. Reuvers Company insiderDirector · last 11 Mar 20250 · 13

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202575.9%
Operating profit marginFY 2025 · to 31 Dec 20258.9%
Free cash flow marginFY 2025 · to 31 Dec 202512.3%
Return on capital employedFY 2025 · to 31 Dec 202512.6%
Cash conversionFY 2025 · to 31 Dec 2025224%
Research spendFY 2025 · to 31 Dec 20252.6%
Share count trendFY 2025 · to 13 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$83.4M
Free cash flowFY 2025 · to 31 Dec 2025$40.4M

Analyst forecasts

No analyst forecasts yet.